Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer
暂无分享,去创建一个
[1] M. Greaves,et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.
[2] Amanda G. Fisher,et al. A molecular clone of HTLV-III with biological activity , 1985, Nature.
[3] A. Dalgleish,et al. Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.
[4] G. Nakamura,et al. Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. , 1986, Science.
[5] G. Nakamura,et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor , 1987, Cell.
[6] N. Chang,et al. Monoclonal Antibodies that Neutralize HIV–1 Virions and Inhibit Syncytium Formation by Infected Cells , 1987, Bio/Technology.
[7] C. Boucher,et al. Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. , 1988, AIDS.
[8] G. Pauli,et al. Fine structure of human immunodeficiency virus (HIV), immunolocalization of structural proteins and virus-cell relation , 1988 .
[9] R. Weiss,et al. Neutralizing monoclonal antibodies to the AIDS virus. , 1988, AIDS.
[10] A J Langlois,et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Goedert,et al. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. , 1988, Science.
[12] H. Lyerly,et al. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. , 1988, AIDS research and human retroviruses.
[13] J. Skehel,et al. Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. , 1989, Virology.
[14] T. Chang,et al. A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. , 1989, Journal of immunology.
[15] T. H. Lee,et al. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.
[16] M. Emerman,et al. Effects of mutations in hyperconserved regions of the extracellular glycoprotein of human immunodeficiency virus type 1 on receptor binding , 1989, Journal of virology.
[17] K. Ikuta,et al. Expression of human immunodeficiency virus type 1 (HIV-1) gag antigens on the surface of a cell line persistently infected with HIV-1 that highly expresses HIV-1 antigens. , 1989, Virology.
[18] R. Liskamp,et al. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. , 1989, The Journal of general virology.
[19] A. Profy,et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.
[20] J. Sodroski,et al. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding , 1990, Journal of virology.
[21] L. Bacheler,et al. HIV-1 neutralizing monoclonal antibodies induced by a synthetic peptide. , 1990, AIDS research and human retroviruses.
[22] L. Eckler,et al. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. , 1990, Journal of immunology.
[23] P. Earl,et al. Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[24] J. Robinson,et al. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. , 1990, AIDS research and human retroviruses.
[25] D. Dormont,et al. Design and trials of AIDS vaccines. , 1990, Immunology today.
[26] J. Levy,et al. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles , 1990, Journal of virology.
[27] P. Earl,et al. Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain , 1990, Journal of virology.
[28] M. Hilgartner,et al. A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. , 1991, Research in virology.
[29] Q. Sattentau,et al. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.
[30] D. Ho,et al. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Ho,et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody , 1991, Journal of virology.
[32] K. Steimer,et al. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. , 1991, Science.
[33] J. Sodroski,et al. Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody , 1991, Journal of virology.
[34] T. Hideshima,et al. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. , 1991, Journal of immunology.
[35] J. Laman,et al. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain , 1992, Journal of virology.
[36] J. Sodroski,et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein , 1992, Journal of virology.
[37] S. Zolla-Pazner,et al. Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. , 1992, AIDS research and human retroviruses.
[38] J. Moore,et al. Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. , 1992, AIDS research and human retroviruses.
[39] J. McKeating,et al. Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gpl20 , 1992 .
[40] S. Zolla-Pazner,et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.
[41] D. Ho,et al. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 , 1992, Journal of virology.
[42] G K Lewis,et al. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop , 1993, Journal of virology.
[43] J. Sodroski,et al. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody , 1993, Journal of virology.
[44] N. Sullivan,et al. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120 , 1993, Journal of virology.
[45] Q. Sattentau,et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domains , 1993, Journal of virology.
[46] J. Sodroski,et al. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding , 1993, Journal of virology.
[47] Q. Sattentau,et al. Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding , 1993, Journal of virology.
[48] J. Levy. Pathogenesis of human immunodeficiency virus infection , 1989, Microbiological reviews.
[49] J. Moore,et al. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans , 1993, Journal of virology.
[50] S. Zolla-Pazner,et al. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. , 1994, Journal of immunology.
[51] P. Charneau,et al. Fusion from without directed by human immunodeficiency virus particles , 1994, Journal of virology.
[52] P. Berman,et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.
[53] M. Reitz,et al. Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions , 1995, Journal of virology.
[54] A. Trkola,et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B , 1995, Journal of virology.
[55] C. Barbas,et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120 , 1995, Journal of virology.
[56] Q. Sattentau,et al. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. , 1995, Virology.